免疫检查点抑制剂安全性概况:意大利自发报告系统数据库分析
本研究基于意大利自发不良反应报告系统2011-2018年数据,分析伊匹木单抗、纳武利尤单抗、帕博利珠单抗和阿替利珠单抗相关ADR报告。共2217份(0.7%)报告,48.8%为严重报告;检测到缺血性心脏病、心力衰竭等潜在新安全信号。
要点
- ICI相关ADR报告以纳武利尤单抗为主(72.2%),严重报告占48.8%。
- 抗CTLA-4药物结肠炎、垂体炎、皮肤事件更多,PD-1/PD-L1药物肌肉骨骼、肺炎、甲状腺事件更多。
核心结论
- ICI最常见安全问题是免疫相关不良事件,包括全身、胃肠和呼吸系统疾病。
- 检测到缺血性心脏病和心力衰竭等潜在新安全信号,需进一步研究。
研究设计与样本
- 基于意大利自发报告系统2011-2018年数据的描述性分析。
- 纳入伊匹木单抗、纳武利尤单抗、帕博利珠单抗和阿替利珠单抗相关ADR报告。
- 采用报告比值比(ROR)评估ADR报告的不成比例性。
- 与所有其他可疑药物或所有其他抗肿瘤药物两个参照组比较。
主要发现
- 共2217份(0.7%)报告归因于ICI:纳武利尤单抗72.2%、伊匹木单抗14.3%、帕博利珠单抗10.3%、阿替利珠单抗3.5%。
- ICI相关ADR报告主要涉及男性(65%),中位年龄67岁(四分位距59-73)。
- 严重报告占48.8%。
- 除感染外,与其他抗肿瘤药物比较结果相似。
临床怎么用
- 临床应关注ICI治疗患者的内分泌、肝胆、呼吸及感染相关不良事件。
- 使用抗CTLA-4药物时警惕结肠炎、垂体炎和皮肤反应,使用PD-1/PD-L1抑制剂时关注肌肉骨骼症状、肺炎和甲状腺功能异常。
- 对缺血性心脏病和心力衰竭等潜在新信号保持监测。
局限性
- 研究基于自发报告系统,存在报告偏倚和低报漏报可能。
- 未报告报告率分母,无法计算真实发生率。
- 描述性分析不能确立因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To provide an overview of immune checkpoint inhibitors (ICIs) safety profile using the Italian spontaneous adverse drug reaction (ADR) reporting system. METHODS: We selected all ADR reports attributed to ipilimumab (CTLA-4 inhibitor), nivolumab, pembrolizumab, atezolizumab (PD-1/PD-L1 inhibitors) from the Italian spontaneous reporting system (2011-2018). Descriptive analyses of reports for ICIs have been conducted. Time to onset of adverse effects was stratified by system organ class. Reporting odds ratio was used as measure of ADR reporting disproportionality. ICI-related ADR reports were compared with 2 reference groups, i.e. all other suspected drugs or all other antineoplastic agents. RESULTS: Overall, 2217 (0.7%) reports were related to ICIs (nivolumab: 72.2% of those reports; ipilimumab: 14.3%; pembrolizumab: 10.3%; and atezolizumab: 3.5%). ICI-related ADR reports mostly involved males (65%) and median age was 67 (interquartile range 59-73) years. Serious reports accounted for 48.8%. Frequencies of endocrine, general, hepatobiliary, metabolism, musculoskeletal, respiratory disorders, infections and neoplasms were significantly higher for ICIs than for all other drugs (P < .001). Except for infections, similar results emerged through comparison with other anticancer drugs. Colitis, hypophysitis and skin disorders were more frequently reported for anti-CTLA-4 drugs than PD-1/PD-L1 ICIs, and the opposite for musculoskeletal effects, pneumonia, and thyroid dysfunctions. ICIs were disproportionally associated also with less known risks, e.g. ischaemic heart disease, cardiac failure and optic nerve disorders. CONCLUSION: The most frequently reported safety issues were probably immune-related adverse events including general, gastrointestinal and respiratory disorders. Potentially emerging safety signals, such as ischaemic heart disease and cardiac failure, requiring further investigation were detected.
引用
- Cutroneo PM, Isgrò V, Ientile V, et al. Safety profile of immune checkpoint inhibitors: An analysis of the Italian spontaneous reporting system database. Br J Clin Pharmacol. 2020. PMID: 32495965. doi:10.1111/bcp.14413
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。